Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

Niloefar Ahmadi Bidakhvidi(KU Leuven), Christophe M. Deroose(KU Leuven), Karolien Goffin(KU Leuven), Kristiaan Nackaerts(Heidelberg University), Kristof Baete(KU Leuven), Jeroen Dekervel(Universitair Ziekenhuis Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
Cancers
December 28, 2021
10.3390/cancers14010129
Cited by 48

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k